文献速递免疫规划慢病防控与筛查妇幼与学校卫生

接受免疫抑制治疗的风湿病患儿接种减毒MMR/V加强疫苗是安全的:多中心回顾性数据收集

Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection.
PubMed 文献 · Vaccine · 2020-01-24

该多中心回顾性研究收集了10个国家13个儿童风湿病中心的234例患者数据,其中211例(90.2%)为幼年特发性关节炎。患者在免疫抑制治疗期间接种减毒麻疹-腮腺炎-风疹(MMR)或麻疹-腮腺炎-风疹-水痘(MMR/V)加强疫苗,未报告疫苗相关感染,也无患者出现疾病 flare。结论认为减毒MMR/V加强疫苗对接受免疫抑制治疗的风湿病患儿是安全的,并强化了PReS的建议。

要点

  • 234例患儿中211例(90.2%)为JIA,110例(47%)在用药下处于缓解期。
  • 接种后未报告麻疹、风疹、腮腺炎或水痘的疫苗相关感染,也无患者出现疾病 flare。
  • PReS建议免疫抑制治疗患者接种减毒活疫苗可个体化考虑,权衡接种获益与疫苗诱导感染风险。

核心结论

  • 在这项回顾性研究中,减毒MMR/V加强疫苗对接受免疫抑制治疗的风湿病患儿是安全的。
  • 该数据强化了PReS的建议:免疫抑制治疗患者接种减毒活疫苗可个体化考虑,权衡接种获益与疫苗诱导感染风险。
  • 这些数据为PReS疫苗接种研究组计划开展的前瞻性数据收集研究提供了基础。

研究设计与样本

  • 多中心回顾性数据收集,来自10个国家的13个儿童风湿病中心,共234例患者。
  • 患者为幼年特发性关节炎(JIA)和其他风湿病,在免疫抑制治疗期间接种减毒MMR或MMR/V加强疫苗。
  • 诊断时平均年龄5 ± 2.7岁,67%为女孩;211例(90.2%)为JIA,110例(47%)在用药下处于缓解期。
  • 疾病活动度低者37%,高者8%,中者8%。

主要发现

  • 124例在接受甲氨蝶呤(MTX)期间接种MMR/V加强疫苗,其中3例报告局部轻度不良事件(AE)。
  • 62例在接受MTX + 生物制剂期间接种,9例报告轻度AE;9例接受两种改善病情抗风湿药(DMARD)联合治疗者中,9例报告轻度AE。
  • 39例在接受生物制剂期间接种,其中1例报告接种后一天发热。
  • 未报告麻疹、风疹、腮腺炎或水痘的疫苗相关感染,无患者出现疾病 flare,包括高疾病活动度者。

关键数值与推荐

  • PReS建议:免疫抑制治疗患者接种减毒活疫苗可个体化考虑,权衡接种获益与疫苗诱导感染风险。

临床怎么用

  • 作者结论认为减毒MMR/V加强疫苗对接受免疫抑制治疗的风湿病患儿是安全的。
  • PReS建议免疫抑制治疗患者接种减毒活疫苗可个体化考虑,权衡接种获益与疫苗诱导感染风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To collect retrospective data of patients with Juvenile Idiopathic Arthritis (JIA) and other rheumatic diseases who received live attenuated booster measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMR/V) during treatment with immunosuppressive therapy. RESULTS: Data from 13 pediatric rheumatology centers in 10 countries, including 234 patients, were collected. Mean age at diagnosis was 5 ± 2.7 years, 67% were girls. Among them, 211 (90.2%) had JIA and 110 (47%) were in remission on medication. Disease activity was low in 37%, high in 8%, and moderate in 8%. One hundred-twenty-four received MMR/V booster while on methotrexate (MTX); 3 reported local mild adverse events (AE). Among 62 on MTX + biologics and 9 patients who received a combination of 2 disease modifying antirheumatic drugs (DMARDs), 9 reported mild AE. Among 39 on biologics, 1 reported fever one day after booster vaccination. No vaccine-related infection of measles, rubella, mumps or varicella was reported, none of the patients developed disease flare, including those with high disease activity. CONCLUSIONS: In this retrospective study, live-attenuated MMR/V booster vaccines were safe for children with rheumatic diseases, on immunosuppressive therapies. This strengthens the Paediatric Rheumatology European Society (PReS) recommendation that vaccination with live attenuated vaccines in patients on immunosuppressive therapies can be considered individually, weighing the benefit of vaccination against the risk of inducing infection through vaccination. These data provide the basis for a prospective data collection study, planned by the PReS vaccination study group.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Uziel Y, Moshe V, Onozo B, et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. Vaccine. 2020. PMID: 31987692. doi:10.1016/j.vaccine.2020.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。